ThomasRSciasciaMD

Neurology • Belmont, MA

Physician

Join to view full profile

Are you Dr. Sciascia?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 49 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
108 Oliver Rd
Belmont, MA 02478
Phone+1 617-484-2267

Summary

Dr. Thomas Sciascia, MD is a board certified neurologist in Belmont, Massachusetts. He is currently licensed to practice medicine in Massachusetts and Tennessee.

Education & Training

Boston University Medical CenterResidency, Neurology, 1981 - 1984
University of MichiganInternship, Internal Medicine, 1979 - 1980
Columbia University Vagelos College of Physicians and SurgeonsClass of 1979

Certifications & Licensure

MA State Medical License 1981 - 2025
TN State Medical License 1996 - 1998
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Start of enrollment: 2014 Jun 01
Completed
Phase 2, Phase 3
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis Start of enrollment: 2015 Mar 01
Completed
Phase 2, Phase 3
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis Start of enrollment: 2015 Aug 15
Completed
Phase 2, Phase 3
Oral Abuse Potential Study of Nalbuphine Start of enrollment: 2018 May 29
Completed
Phase 1
Nalbuphine ER Effects of Liver Disease on Pharmacokinetics and Itch Start of enrollment: 2018 Oct 24
Active, not recruiting
Phase 1
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough Start of enrollment: 2019 Aug 08
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

42 citations
Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
Amale Hawi, Harry Alcorn, Jolene K. Berg, Carey Hines, Howard Hait
BMC Nephrology. 2015-04-08
57 citations
A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial.
David A. Lynch, Steven M. Willi, Robert B. Wilson, M. Grazia Cotticelli, Karlla W. Brigatti
Movement Disorders. 2012-07-01
7 citations
Use of an Adaptive Study Design in Single Ascending-Dose Pharmacokinetics of A0001 (α-Tocopherylquinone) in Healthy Male Subjects
Amale Hawi, Sarah Heald, Thomas Sciascia
Journal of Clinical Pharmacology. 2012-01-01

Press Mentions

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical OfficerNovember 14th, 2022
Phase 2 Trial of Haduvio for Chronic Cough Due to IPF Again Enrolling in UKOctober 23rd, 2020